186 related articles for article (PubMed ID: 36175453)
1. A preclinical model of cutaneous melanoma based on reconstructed human epidermis.
Leikeim A; Wußmann M; Schmidt FF; Neto NGB; Benz F; Tiltmann K; Junger C; Monaghan MG; Schilling B; Groeber-Becker FK
Sci Rep; 2022 Sep; 12(1):16269. PubMed ID: 36175453
[TBL] [Abstract][Full Text] [Related]
2. Metabolic targeting synergizes with MAPK inhibition and delays drug resistance in melanoma.
Brummer C; Faerber S; Bruss C; Blank C; Lacroix R; Haferkamp S; Herr W; Kreutz M; Renner K
Cancer Lett; 2019 Feb; 442():453-463. PubMed ID: 30481565
[TBL] [Abstract][Full Text] [Related]
3. Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study.
Ribas A; Gonzalez R; Pavlick A; Hamid O; Gajewski TF; Daud A; Flaherty L; Logan T; Chmielowski B; Lewis K; Kee D; Boasberg P; Yin M; Chan I; Musib L; Choong N; Puzanov I; McArthur GA
Lancet Oncol; 2014 Aug; 15(9):954-65. PubMed ID: 25037139
[TBL] [Abstract][Full Text] [Related]
4. Human papillomavirus-negative epithelial proliferations resembling condylomata acuminata in a patient receiving vemurafenib for Stage IV melanoma.
Peters MA; Geukes Foppen MH; Blank CU; Crijns MB
J Cancer Res Ther; 2020; 16(1):170-172. PubMed ID: 32362631
[TBL] [Abstract][Full Text] [Related]
5. The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma.
Kim A; Cohen MS
Expert Opin Drug Discov; 2016 Sep; 11(9):907-16. PubMed ID: 27327499
[TBL] [Abstract][Full Text] [Related]
6. Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor.
Seghers AC; Wilgenhof S; Lebbé C; Neyns B
Melanoma Res; 2012 Dec; 22(6):466-72. PubMed ID: 22584957
[TBL] [Abstract][Full Text] [Related]
7. BRAF
Lunavat TR; Cheng L; Einarsdottir BO; Olofsson Bagge R; Veppil Muralidharan S; Sharples RA; Lässer C; Gho YS; Hill AF; Nilsson JA; Lötvall J
Proc Natl Acad Sci U S A; 2017 Jul; 114(29):E5930-E5939. PubMed ID: 28684402
[TBL] [Abstract][Full Text] [Related]
8. Semaphorin-5A downregulation is associated with enhanced migration and invasion of BRAF-positive melanoma cells under vemurafenib treatment in melanomas with heterogeneous BRAF status.
Komina AV; Palkina NV; Aksenenko MB; Lavrentev SN; Moshev AV; Savchenko AA; Averchuk AS; Rybnikov YA; Ruksha TG
Melanoma Res; 2019 Oct; 29(5):544-548. PubMed ID: 31116162
[TBL] [Abstract][Full Text] [Related]
9. BRAF inhibition and the spectrum of granulomatous reactions.
Pham JP; Star P; Phan K; Loh Y; Joshua AM; Smith A
J Am Acad Dermatol; 2022 Sep; 87(3):605-613. PubMed ID: 34715287
[TBL] [Abstract][Full Text] [Related]
10. Ocoxin Increases the Antitumor Effect of BRAF Inhibition and Reduces Cancer Associated Fibroblast-Mediated Chemoresistance and Protumoral Activity in Metastatic Melanoma.
Benedicto A; Hernandez-Unzueta I; Sanz E; Márquez J
Nutrients; 2021 Feb; 13(2):. PubMed ID: 33669949
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma.
Tap WD; Gong KW; Dering J; Tseng Y; Ginther C; Pauletti G; Glaspy JA; Essner R; Bollag G; Hirth P; Zhang C; Slamon DJ
Neoplasia; 2010 Aug; 12(8):637-49. PubMed ID: 20689758
[TBL] [Abstract][Full Text] [Related]
12. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
[TBL] [Abstract][Full Text] [Related]
13. Histopathologic characteristics of therapy-associated cutaneous neoplasms with vemurafenib, a selective BRAF kinase inhibitor, used in the treatment of melanoma.
Sufficool KE; Hepper DM; Linette GP; Hurst EA; Lu D; Lind AC; Cornelius LA
J Cutan Pathol; 2014 Jul; 41(7):568-75. PubMed ID: 24641301
[TBL] [Abstract][Full Text] [Related]
14. Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients.
Sullivan RJ; Hamid O; Gonzalez R; Infante JR; Patel MR; Hodi FS; Lewis KD; Tawbi HA; Hernandez G; Wongchenko MJ; Chang Y; Roberts L; Ballinger M; Yan Y; Cha E; Hwu P
Nat Med; 2019 Jun; 25(6):929-935. PubMed ID: 31171876
[TBL] [Abstract][Full Text] [Related]
15. Differential inhibition of ex-vivo tumor kinase activity by vemurafenib in BRAF(V600E) and BRAF wild-type metastatic malignant melanoma.
Tahiri A; Røe K; Ree AH; de Wijn R; Risberg K; Busch C; Lønning PE; Kristensen V; Geisler J
PLoS One; 2013; 8(8):e72692. PubMed ID: 24023633
[TBL] [Abstract][Full Text] [Related]
16. p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib.
Krayem M; Journe F; Wiedig M; Morandini R; Najem A; Salès F; van Kempen LC; Sibille C; Awada A; Marine JC; Ghanem G
Eur J Cancer; 2016 Mar; 55():98-110. PubMed ID: 26790143
[TBL] [Abstract][Full Text] [Related]
17. T-Type Calcium Channels as Potential Therapeutic Targets in Vemurafenib-Resistant BRAF
Barceló C; Sisó P; Maiques O; García-Mulero S; Sanz-Pamplona R; Navaridas R; Megino C; Felip I; Urdanibia I; Eritja N; Soria X; Piulats JM; Penin RM; Dolcet X; Matías-Guiu X; Martí RM; Macià A
J Invest Dermatol; 2020 Jun; 140(6):1253-1265. PubMed ID: 31877318
[TBL] [Abstract][Full Text] [Related]
18. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion-Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
Lancet Oncol; 2018 May; 19(5):603-615. PubMed ID: 29573941
[TBL] [Abstract][Full Text] [Related]
19. Beneficial effects of RAF inhibitor in mutant BRAF splice variant-expressing melanoma.
Hartsough EJ; Basile KJ; Aplin AE
Mol Cancer Res; 2014 May; 12(5):795-802. PubMed ID: 24520098
[TBL] [Abstract][Full Text] [Related]
20. A Novel Plant Sesquiterpene Lactone Derivative, DETD-35, Suppresses BRAFV600E Mutant Melanoma Growth and Overcomes Acquired Vemurafenib Resistance in Mice.
Feng JH; Nakagawa-Goto K; Lee KH; Shyur LF
Mol Cancer Ther; 2016 Jun; 15(6):1163-76. PubMed ID: 27048951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
